Acquired Immunodeficiency Syndrome (AIDS) Epidemiology Forecast 2025-2034

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 39.9 million people worldwide were living with HIV (the virus that causes AIDS) in 2023. The estimates suggest that 38.6 million adults and 1.4 million children were affected, out of which 53% were women and girls.

Acquired Immunodeficiency Syndrome (AIDS) Epidemiology Forecast Report Coverage

The “Acquired Immunodeficiency Syndrome (AIDS) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of acquired immunodeficiency syndrome (AIDS). It projects the future incidence and prevalence rates of acquired immunodeficiency syndrome (AIDS) across various populations. The study covers age, gender, and type as major determinants of the acquired immunodeficiency syndrome (AIDS)-affected population. The report highlights patterns in the prevalence of acquired immunodeficiency syndrome (AIDS) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of acquired immunodeficiency syndrome (AIDS) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Acquired Immunodeficiency Syndrome (AIDS) Disease Overview

Acquired Immunodeficiency Syndrome (AIDS) is considered the final stage of HIV (human immunodeficiency virus) infection, characterized by severe damage to the immune system due to the prolonged presence of HIV in the body. When HIV progresses to AIDS, the CD4 count falls below 200 cells per cubic millimeter of blood and there is a significant decline in immune function. This makes the affected individuals vulnerable to infections and certain cancers, such as pneumonia, tuberculosis, and Kaposi’s sarcoma.

Acquired Immunodeficiency Syndrome (AIDS): Treatment Overview

Antiretroviral therapy (ART) is primarily involved in the treatment of acquired immunodeficiency syndrome. This therapy consists of a combination of HIV medications that help in suppressing the virus and preventing its progression. Nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors are some of the medications from various drug classes that are present in antiretroviral therapy. Additionally, patients may opt for prophylactic treatments to prevent infections like pneumonia or tuberculosis.

Epidemiology

The acquired immunodeficiency syndrome (AIDS) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for acquired immunodeficiency syndrome (AIDS) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for acquired immunodeficiency syndrome (AIDS) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• HIV/AIDS is considered one of the most fatal infectious diseases in the world, with nearly 1 million people dying from the condition every year. In some countries, HIV/AIDS is the leading cause of death.
• In 2023, approximately 39.9 million people were living with HIV worldwide. Of these, 38.6 million were adults aged 15 and older, and 1.4 million were children aged 0-14. About 53% of all people with HIV were women and girls.
• In 2023, roughly 86% of people with HIV worldwide were aware of their HIV status. However, around 5.4 million people were unaware they had HIV and still required access to testing services.
• New HIV infections dropped 12% from 36,200 in 2018 to 31,800 in 2022, with a 30% decrease among those aged 13-24, according to the CDC. Increased use of pre-exposure prophylaxis, viral suppression, and HIV testing likely contributed to the decline in estimated HIV infections.

Country-wise Acquired Immunodeficiency Syndrome (AIDS) Epidemiology

The acquired immunodeficiency syndrome (AIDS) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of acquired immunodeficiency syndrome (AIDS) varies between countries owing to differences in HIV prevention programs, awareness, socioeconomic factors, and the availability of treatment and testing services, among others. In the United States, around 1.2 million people have HIV and nearly 13% of the affected individuals aren’t aware of their HIV status.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of acquired immunodeficiency syndrome (AIDS) based on several factors.
• Acquired Immunodeficiency Syndrome (AIDS) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of acquired immunodeficiency syndrome (AIDS) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of acquired immunodeficiency syndrome (AIDS) epidemiology in the 8 major markets?
• What will be the total number of patients with acquired immunodeficiency syndrome (AIDS) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of acquired immunodeficiency syndrome (AIDS) in the 8 major markets in the historical period?
• Which country will have the highest number of acquired immunodeficiency syndrome (AIDS) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of acquired immunodeficiency syndrome (AIDS) during the forecast period of 2025-2034?
• What are the currently available treatments for acquired immunodeficiency syndrome (AIDS)?
• What are the disease risks, signs, symptoms, and unmet needs of acquired immunodeficiency syndrome (AIDS)?

This product will be delivered within 3-5 business days.